Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes.

Diabetes care - 1 Nov 2016

Dawed Adem Y, Donnelly Louise, Tavendale Roger, Carr Fiona, Leese Graham, Palmer Colin N A, Pearson Ewan R, Zhou Kaixin

Abstract excerpt

OBJECTIVE: Thiazolidinediones (TZDs) are putatively transported into the liver by OATP1B1 (encoded by SLCO1B1) and metabolized by CYP450 2C8 enzyme (encoded by CYP2C8). While CYP2C8*3 has been shown to alter TZD pharmacokinetics, it has not been shown to alter efficacy. RESEARCH DESIGN AND METHODS: We genotyped 833 Scottish patients with type 2 diabetes treated with pioglitazone or rosiglitazone and jointly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C8
Share to Hypoglycemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Linear Models

Share to Liver-Specific Organic Anion Transporter 1

Share to Pioglitazone

Share to Rosiglitazone

Share to Scotland

Share to Thiazolidinediones

Source

Identifiers

PMID: 27271184
DOI: 10.2337/dc15-2464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes.PMID 27271184Read ↗

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.Semantic proximity Read ↗

Pharmacogenetics and personalized treatment of type 2 diabetesSemantic proximity Read ↗

The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Semantic proximity Read ↗

Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.Semantic proximity Read ↗

Pharmacogenetics of thiazolidinedione therapy.Semantic proximity Read ↗

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Semantic proximity Read ↗

Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.Semantic proximity Read ↗

CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Semantic proximity Read ↗

SLCO1B1 polymorphism and oral antidiabetic drugs.Semantic proximity Read ↗

Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.Semantic proximity Read ↗

Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.Semantic proximity Read ↗

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.